(Total Views: 197)
Posted On: 12/09/2019 4:49:49 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Updates on Commercialization of Cancer Quest 2020 Initiative
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced updates on the commercialization of its CancerQuest 2020 initiative. According to the update, the Company is confident that its first predictive model of ovarian cancer will be ready for initial commercialization in revenue generating projects with Pharma in the first quarter of 2020. Predictive Oncology’s Helomics division has been working closely with its sequencing partner to optimize and scale the generation of both genomic and transcriptomic data and has sequenced the first batch of ovarian tumors. The Company anticipates that the sequencing of the remainder of the 400 ovarian cancer subjects will proceed as planned, establishing another milestone in its CancerQuest 2020 initiative and path to commercialization.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced updates on the commercialization of its CancerQuest 2020 initiative. According to the update, the Company is confident that its first predictive model of ovarian cancer will be ready for initial commercialization in revenue generating projects with Pharma in the first quarter of 2020. Predictive Oncology’s Helomics division has been working closely with its sequencing partner to optimize and scale the generation of both genomic and transcriptomic data and has sequenced the first batch of ovarian tumors. The Company anticipates that the sequencing of the remainder of the 400 ovarian cancer subjects will proceed as planned, establishing another milestone in its CancerQuest 2020 initiative and path to commercialization.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
